- 17:20Israel foreign minister optimistic about Gaza ceasefire and hostage deal amid ongoing talks
- 16:50US sanctions target firms tied to Iranian oil sales, citing links to Quds Force
- 16:20New Gaza-bound aid mission to challenge Israeli blockade
- 15:50Severe thunderstorms to strike Moroccan regions amid ongoing heatwaves
- 15:20Morocco advances overhaul of criminal procedure code to modernize justice system
- 14:45Congo’s football chief accused of embezzling $1.3 million in FIFA funds
- 14:20Handala mission: Freedom Flotilla launches new humanitarian voyage to Gaza
- 13:30Transfer talks stall as Hamza Igamane's Lille move hits a snag
- 12:20Morocco reduces pre-trial detention rates to historic low
Follow us on Facebook
Urgent recall of Aureomycine 1% ointment due to non-compliance
The Moroccan Agency for Medicines and Health Products (AMMPS) has mandated the immediate recall of several batches of the ophthalmic ointment Aureomycine 1%, commonly known as the yellow ointment, which contains chlorotetracycline hydrochloride in 5 g tubes.
This decision follows the identification of a non-compliance issue regarding the product's appearance, revealed during real-condition stability testing.
The affected batches, numbered 22043, 22046, and 23001, must be promptly withdrawn from wholesalers, pharmacies, and hospital facilities in accordance with AMMPS instructions. The agency has urged health professionals and distributors to halt all sales and usage of the Aureomycine 1% ointment from the specified batches.
Additionally, Promopharm, the pharmaceutical establishment responsible for manufacturing these products, is required to submit a detailed report to AMMPS. This report should include an account of the quantities distributed and retrieved, along with a record of the destruction of the recalled batches.
Furthermore, an informational letter intended for health professionals must be approved by the administration before it can be disseminated.
Comments (0)